ALK-Abelló A/S

alk

ALK-Abelló A/S is an international pharmaceutical company devoted to improve the lives of people with allergies by developing pharmaceuticals products that target the cause of allergy.

ALK-Abelló A/S is the world leader in allergy vaccination (immunotherapy) – a unique treatment including a protective immune response that reduces and potentially halts the allergic reaction.

For further information: www.alk.net

Lundbeckfonden

News

The Lundbeck Foundation awards € 1 million for pioneering research on strokes in the small blood vessels in the brain
5. March 2019
The Brain Prize 2019: French neuroscientists honoured for outstanding research into small vessel strokes in the brain
5. March 2019
Danish scientists shed new light on overwhelming need to sleep
19. February 2019